CD4 and prostate carcinoma: Although there was no significant difference in immune cell number in prostate cancer samples (Figure 1E), several transcriptional differences in immune cells were evident; Antigen presentation and processing pathway genes were significantly reduced in prostate MNPs in cancer samples compared with normal prostate (Figure 5A), consistent with a widespread attenuation of CD4 T cell activation, a process critical for the generation of antitumor adaptive immune responses.